A newly introduced diazo reagent enables access to a range of azole-based primary sulfonamides highly relevant in the context of inhibition of therapeutically valuable isoforms of carbonic anhydrase. This new synthetic strategy will support the discovery of novel, isoform-selective inhibitors of carbonic anhydrase within the poorly explored azole chemical space.